Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1"

Affiliations

• ¹ From the Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians University Munich (T.P., M.T., Z.Z., E.L., L.N., I.S., C.S.).
• ² DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Germany (T.P., M.T., E.L., L.N., C.S.).
• ³ Department of Cardiology, Pulmonology and Vascular Medicine, Cardiovascular Research Institute Düsseldorf (CARID) (L.D., S.A., P.M., C.H., R.M., A.A., D.Z., C.J., N.G., T.Z., M.K., A.P.), Medical Faculty of the Heinrich Heine University Düsseldorf, Germany.
• ⁴ Institute of Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Medical Center Düsseldorf, Germany (T. Hoffmann).
• ⁵ Institute of Pathophysiology, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Germany (B.L.).
• ⁶ Institute of Pharmacology and Clinical Pharmacology (T. Hohlfeld), Medical Faculty of the Heinrich Heine University Düsseldorf, Germany.